Detalles de la búsqueda
1.
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
Ann Surg Oncol
; 30(13): 8353-8361, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37658272
2.
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Ann Surg Oncol
; 2022 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35378634
3.
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
Surg Oncol
; 45: 101885, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36436423
4.
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
JCO Precis Oncol
; 6: e2200197, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36108259
5.
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
JCO Precis Oncol
; 6: e2100463, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35476550
Resultados
1 -
5
de 5
1
Próxima >
>>